{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Zurnai is a prescription medication containing nalmafene hydrochloride, an opioid antagonist used to reverse opioid overdose effects. It's administered as an injection via autoinjector into the muscle or under the skin, with each dose providing 1.5 mg in 0.5 mL. Manufactured by Purdue Pharma L.P., it's approved for emergency use. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Nalmefene hydrochloride \u2014 ANDA 218590 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218590", "mediaType": "text/html", "title": "Nalmefene hydrochloride"}], "identifier": "ANDA218590", "issued": "2016-09-16", "keyword": ["drug-information", "medications", "health-care", "fda", "drug"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Nalmefene hydrochloride"}